Supreme Court Mifepristone Decision Sets High Bar For FDA Suits, But Risks To Agency Authority Linger

 
• By Sarah Karlin-Smith
  
female athlete performing high jump
The US Supreme Court abortion pill opinion sets a high bar for FDA lawsuits, but future tests of FDA's authority remain a risk. • Source: Shutterstock
HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

SpotifyApple PodcastsWebsite

More from United States

More from North America